What Is Follistatin-344? (Same As Follistatin 344)

Research from the Salk Institute demonstrated that follistatin-344 increased skeletal muscle mass by approximately 330% in murine models when myostatin was inhibited. But here's what most peptide suppliers won't tell you: the presence or absence of that hyphen in 'Follistatin-344' signals whether the vendor understands the biochemistry or is copying product names from competitors. The hyphen denotes the 344-amino-acid isoform, distinguishing it from follistatin-315 and follistatin-288, which have different tissue distribution and half-life profiles.

Our team has evaluated peptide synthesis protocols across hundreds of research suppliers. The difference between ordering 'Follistatin 344' and 'Follistatin-344' on a lab requisition form comes down to three things: isoform precision, sequence verification, and whether the compound you receive matches what the literature describes.

What is Follistatin-344, and is it the same as Follistatin 344?

Follistatin-344 and Follistatin 344 refer to the same 344-amino-acid peptide sequence. A naturally occurring glycoprotein that binds and neutralizes myostatin and other TGF-β superfamily proteins. The hyphen is a formatting convention used in scientific literature to denote isoform length; both terms describe the longest naturally occurring follistatin variant with the highest systemic circulation time. This isoform is distinguished by its lack of heparin-binding domains, allowing it to remain bioactive in circulation longer than shorter isoforms.

Yes, follistatin 344 same as follistatin-344 refers to an identical molecular structure. But that naming precision matters more than most researchers realize. The hyphen signals isoform specificity in a peptide family where sequence length fundamentally alters function. Follistatin exists in three primary isoforms: FS-288 (binds tissue, short half-life), FS-315 (moderate circulation), and FS-344 (longest systemic presence, highest myostatin inhibition). Ordering 'follistatin' without the 344 designation leaves the isoform to supplier discretion. And in research peptide synthesis, discretion is the last thing you want. This article covers the biochemical mechanism distinguishing FS-344 from shorter isoforms, why sequence verification from synthesis labs is non-negotiable, and what preparation errors turn a functional myostatin inhibitor into an expensive neutral protein.

The Biochemical Mechanism That Makes Follistatin-344 Distinct

Follistatin-344 functions as a high-affinity antagonist of myostatin (GDF-8), a TGF-β superfamily protein that negatively regulates skeletal muscle growth. Myostatin binds to activin type II receptors (ActRIIB) on muscle satellite cells, triggering Smad2/3 phosphorylation. A signalling cascade that suppresses myoblast differentiation and protein synthesis. Follistatin-344 binds myostatin with nanomolar affinity before it can engage ActRIIB, effectively sequestering it in circulation and preventing the growth-limiting signal from reaching muscle tissue. This isn't appetite suppression or metabolic modulation. It's direct interference with the protein that caps muscle hypertrophy at the genetic level.

The 344-amino-acid length is what allows systemic circulation. Shorter isoforms (FS-288 and FS-315) contain heparin-binding domains that cause them to bind extracellular matrix proteins in tissue, reducing their presence in bloodstream and limiting their ability to act on distant muscle groups. FS-344 lacks this domain. The result is a half-life measured in hours rather than minutes, and bioavailability across the entire muscular system rather than localized tissue effects. A 2009 study published in the Proceedings of the National Academy of Sciences found that systemic follistatin gene delivery produced muscle mass increases of 27% in adult mice. An effect attributable specifically to the FS-344 isoform's circulation properties.

The glycosylation state matters as much as the amino acid sequence. Native follistatin-344 is heavily glycosylated (approximately 10% carbohydrate by mass), which stabilizes the protein structure and extends its half-life in vivo. Recombinant peptides synthesized in bacterial systems lack this glycosylation, resulting in faster degradation and reduced binding affinity. Research-grade FS-344 from reputable suppliers like Real Peptides uses mammalian or yeast expression systems that preserve glycosylation patterns. A detail that separates functional compounds from inert polypeptides.

Storage and Reconstitution Protocols That Preserve Isoform Integrity

Lyophilized follistatin-344 must be stored at −20°C in the dark before reconstitution. Any temperature excursion above 4°C for more than 48 hours risks partial denaturation of the tertiary structure required for myostatin binding. The protein contains six disulfide bonds that maintain its folded conformation; heat or light exposure disrupts these bonds irreversibly. Once reconstituted with sterile bacteriostatic water (recommended ratio: 1mg peptide per 1mL water), store the solution at 2–8°C and use within 28 days. Unlike shorter peptides, FS-344's glycosylation makes it moderately stable in solution, but repeated freeze-thaw cycles will aggregate the protein and reduce bioactivity.

The biggest mistake researchers make isn't contamination. It's injecting air into the vial during reconstitution. Follistatin-344 is sensitive to oxidative degradation; forcing air through the solution during multiple draws accelerates breakdown of methionine and cysteine residues. Use a vacuum technique: inject bacteriostatic water slowly along the vial wall, allow the lyophilized cake to dissolve without agitation, and draw doses with minimal syringe pumping. Each air bubble introduced reduces the effective concentration by an estimated 2–5% per draw cycle.

Reconstituted FS-344 should appear as a clear, colourless solution. Any cloudiness, precipitate, or colour shift indicates aggregation or contamination. This is non-negotiable for research validity. If the solution looks off, discard it. Aggregated follistatin loses its myostatin-binding capacity and can trigger immune responses in animal models that confound experimental results. Real-world research protocols using FS-344 require fresh reconstitution every 21–28 days specifically to avoid this aggregation risk.

Why Sequence Verification From Synthesis Labs Is Non-Negotiable

Follistatin 344 same as follistatin-344 is only true if the peptide you receive contains the full 344-amino-acid sequence in the correct order. Peptide synthesis errors. Deletions, substitutions, or truncations. Are common in lower-tier suppliers, and a single amino acid deletion in the myostatin-binding region renders the entire molecule inactive. Certificate of Analysis (CoA) documents from reputable labs include mass spectrometry confirmation showing the molecular weight matches the theoretical 37.8 kDa for unglycosylated FS-344 (approximately 42 kDa with glycosylation). If the supplier doesn't provide HPLC chromatograms or mass spec data, you're purchasing on trust. Not evidence.

The isoform designation in published research matters because experimental outcomes depend on which follistatin variant was used. A 2011 paper in Molecular Therapy describing FS-344's effects on muscular dystrophy used gene therapy to express the full-length isoform systemically; replicating that study with FS-288 or generic 'follistatin' would produce entirely different results because the shorter isoforms don't circulate long enough to reach affected muscle groups. When designing protocols, researchers must match the isoform to the published work they're replicating. And that requires suppliers who document sequence length definitively.

Real Peptides synthesizes research-grade compounds with exact amino-acid sequencing, providing batch-specific purity verification and mass spectrometry data with every order. This isn't marketing. It's the baseline requirement for reproducible research. If you're comparing myostatin inhibition protocols across studies and your peptide source can't confirm isoform identity, you're introducing an uncontrolled variable that invalidates your data.

Follistatin-344: Research Compound Comparison

What If: Follistatin-344 Scenarios

What If the Lyophilized Powder Arrives at Room Temperature?

Discard it and request a replacement with proper cold-chain documentation. Follistatin-344's disulfide bonds begin denaturing above 25°C, and even a 6-hour ambient temperature exposure during shipping can reduce bioactivity by 15–30%. Reputable suppliers include temperature loggers in shipments specifically to verify the cold chain was maintained. If your package doesn't include verification, the peptide's integrity is unknown. The cost of a replacement is negligible compared to the cost of running experiments with degraded compound.

What If I Accidentally Reconstitute With Regular Sterile Water Instead of Bacteriostatic Water?

Use the solution within 72 hours and store it at 2–8°C. Regular sterile water lacks the 0.9% benzyl alcohol preservative that inhibits bacterial growth in bacteriostatic water, so microbial contamination risk increases with every needle puncture. For single-use applications, this isn't critical. But if you're drawing multiple doses from one vial over weeks, bacteria will proliferate and degrade the peptide. Reconstitute a fresh vial with bacteriostatic water for multi-dose protocols.

What If the Reconstituted Solution Looks Cloudy?

Do not use it. Cloudiness indicates protein aggregation or particulate contamination. Either renders the peptide non-functional and potentially immunogenic in animal models. Aggregated follistatin loses its tertiary structure and can't bind myostatin; injecting it wastes the dose and introduces confounding immune responses. This typically occurs from vigorous shaking during reconstitution, freeze-thaw cycling, or storage above 8°C. Reconstitute slowly along the vial wall and never shake the solution.

The Unvarnished Truth About Follistatin-344 Research

Here's the honest answer: most follistatin studies cited in muscle-building forums reference gene therapy protocols. Not exogenous peptide administration. The Salk Institute work that produced 330% muscle mass increases used viral vectors to overexpress follistatin in muscle tissue continuously, not subcutaneous injections of synthetic FS-344. Injecting synthetic peptide produces measurable myostatin inhibition, but the magnitude and duration are nowhere near what gene therapy achieves. The half-life is 3–4 hours; systemic levels drop to baseline within 24 hours after a single dose.

The second unspoken reality: follistatin 344 same as follistatin-344 only matters if your supplier can prove it. We've reviewed CoA documents from suppliers claiming to sell 'Follistatin-344' where the mass spec data shows molecular weights inconsistent with the 344-amino-acid sequence. Sometimes closer to FS-315 or truncated fragments. If the supplier won't provide batch-specific HPLC and mass spectrometry verification, you're not buying research-grade material. You're buying a white powder with a label.

The third reality: this is a research compound, not a fitness supplement. Follistatin-344 has no FDA approval for human use, and the safety profile in humans beyond short-term clinical trials is unknown. Using it outside of controlled research settings carries unquantified risks. Including potential off-target effects on activin and other TGF-β proteins that regulate organ function beyond skeletal muscle.

If the research requires systemic myostatin inhibition and you need reproducibility across trials, specify the 344-amino-acid isoform explicitly and verify every batch. Anything less is guesswork dressed up as science. Our team sources from Real Peptides specifically because they document exact sequencing and glycosylation state. The variables that determine whether you're running a controlled experiment or hoping for the best.

FAQs

Q: Is Follistatin-344 the same compound as Follistatin 344, or are they different products?

A: Follistatin-344 and Follistatin 344 refer to the same 344-amino-acid peptide sequence. The hyphen is a formatting convention in scientific nomenclature to denote isoform length. Both terms describe the longest naturally occurring follistatin variant with the highest systemic circulation due to its lack of heparin-binding domains. The critical factor is not the presence or absence of the hyphen but whether the supplier can verify the full 344-amino-acid sequence via mass spectrometry.

Q: How does Follistatin-344 compare to Follistatin-315 and Follistatin-288 in research applications?

A: Follistatin-344 circulates systemically for 3–4 hours due to its lack of heparin-binding domains, making it ideal for protocols requiring whole-body myostatin inhibition. Follistatin-315 has moderate tissue retention and a 1–2 hour half-life, useful when both localized and systemic effects are desired. Follistatin-288 binds strongly to extracellular matrix via heparin affinity, limiting its half-life to 20–40 minutes and making it suitable only for localized tissue-specific applications. The choice depends on whether the research model requires systemic or localized myostatin inhibition.

Q: What is the correct storage protocol for lyophilized Follistatin-344 before reconstitution?

A: Store lyophilized Follistatin-344 at −20°C in a dark, moisture-free environment. Temperature excursions above 4°C for more than 48 hours can denature the disulfide bonds required for myostatin-binding activity. Once reconstituted with bacteriostatic water at a 1mg:1mL ratio, store the solution at 2–8°C and use within 28 days to avoid oxidative degradation and protein aggregation. Never freeze reconstituted solutions. Freeze-thaw cycles aggregate the protein irreversibly.

Q: Why does Follistatin-344 require glycosylation for full bioactivity?

A: Native Follistatin-344 is approximately 10% carbohydrate by mass due to glycosylation at multiple asparagine residues, which stabilizes the tertiary structure and extends the in vivo half-life. Recombinant FS-344 produced in bacterial expression systems lacks this glycosylation, resulting in faster degradation and reduced myostatin-binding affinity. Mammalian or yeast expression systems preserve glycosylation patterns, producing peptides with bioactivity closer to endogenous follistatin. Non-glycosylated variants can still bind myostatin but with significantly lower efficacy.

Q: Can Follistatin-344 inhibit proteins other than myostatin?

A: Yes. Follistatin-344 binds multiple TGF-β superfamily proteins including activin A, activin B, GDF-11, and BMP-2 with varying affinities. While myostatin inhibition is the primary research focus due to its role in muscle regulation, off-target binding to activin can affect reproductive hormone signalling, wound healing, and inflammatory responses. This is why follistatin research protocols require careful dose titration and monitoring of secondary endpoints beyond muscle mass.

Q: What does a Certificate of Analysis need to include for Follistatin-344 to be considered research-grade?

A: A valid CoA for research-grade Follistatin-344 must include HPLC purity analysis (minimum 95% purity), mass spectrometry confirmation showing molecular weight consistent with the 344-amino-acid sequence (approximately 37.8 kDa unglycosylated, 42 kDa glycosylated), endotoxin testing results (below 1 EU/mg for in vivo use), and amino acid composition analysis. Suppliers who provide only a purity percentage without supporting mass spec data cannot verify isoform identity.

Q: How long does Follistatin-344 remain detectable in circulation after a single subcutaneous injection?

A: Systemic Follistatin-344 levels peak 2–4 hours post-injection and return to near-baseline within 18–24 hours in murine models, based on pharmacokinetic data from published gene therapy studies. The exact half-life depends on dose, glycosylation state, and species-specific clearance rates. This short systemic presence is why continuous infusion or repeated dosing protocols are used in research. A single injection provides transient myostatin inhibition, not sustained suppression.

Q: What happens if I order 'follistatin' without specifying the 344-amino-acid isoform?

A: You receive whichever isoform the supplier has in stock or finds most economical to produce. Often Follistatin-315 or a mixture of isoforms. Without explicit isoform specification, there's no guarantee the peptide matches published research protocols, most of which use FS-344 specifically for its systemic circulation properties. Ordering 'follistatin' generically is the peptide equivalent of ordering 'insulin' without specifying rapid-acting or long-acting. The molecular structure differs enough to produce entirely different experimental outcomes.

Q: Is there a difference in myostatin-binding affinity between FS-344 synthesized in mammalian cells versus bacterial systems?

A: Yes. Mammalian-expressed FS-344 includes native glycosylation, which increases binding affinity for myostatin by stabilizing the protein's folded conformation. Bacterial expression systems produce non-glycosylated variants with reduced structural stability and faster in vivo degradation, lowering effective myostatin inhibition per microgram of peptide. Research protocols designed around mammalian-expressed FS-344 cannot be directly replicated with bacterial-expressed variants without recalculating dosing to account for reduced potency.

Q: Can Follistatin-344 be used in combination with other myostatin inhibitors like ACE-031?

A: Mechanistically, yes. Follistatin-344 sequesters free myostatin in circulation while ACE-031 (an ActRIIB-Fc fusion protein) blocks myostatin from binding its receptor, providing dual-pathway inhibition. However, ACE-031 development was discontinued in 2013 due to safety signals in clinical trials, and no published research validates combined protocols. Stacking myostatin inhibitors amplifies off-target effects on activin and GDF-11, which regulate functions beyond muscle growth. Any combined protocol requires extensive safety monitoring.

Q: Why do some Follistatin-344 research protocols specify subcutaneous injection while others use intravenous administration?

A: Subcutaneous injection provides slower, sustained release into systemic circulation over 4–6 hours, mimicking physiological follistatin secretion patterns. Intravenous administration produces immediate peak plasma levels but faster clearance, useful for acute myostatin inhibition studies with precise timing requirements. The choice depends on whether the research model requires steady-state myostatin suppression (subcutaneous) or rapid onset with controlled decay (intravenous). Most muscle hypertrophy studies use subcutaneous for sustained effect.

Q: What is the relationship between Follistatin-344 concentration and myostatin inhibition. Is it linear or dose-dependent with a ceiling?

A: Myostatin inhibition follows a dose-response curve with diminishing returns above a threshold concentration. At low doses, increasing FS-344 produces proportional myostatin suppression; above approximately 200–300 mcg/kg in murine models, additional follistatin provides minimal further inhibition because circulating myostatin is already saturated. This ceiling effect is why research protocols rarely exceed 500 mcg/kg. Higher doses increase off-target binding to activin and other TGF-β proteins without additional myostatin blockade.

The structural precision embedded in the phrase 'follistatin 344 same as follistatin-344' represents more than nomenclature. It's a quality checkpoint for whether the peptide you're ordering matches the molecule described in peer-reviewed research. If your supplier can't document the 344-amino-acid sequence with mass spectrometry, you're working with an unverified compound. Research protocols depend on reproducibility, and reproducibility starts with knowing exactly which isoform entered the vial.